By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Advion BioServices today said that under a new, multi-year contract it will provide drug giant Eli Lilly with drug discovery bioanalytical services

In addition, it said that Lilly will transition its drug discovery bioanalytical capability to Advion BioServices, which is a subsidiary of Advion BioSciences. All Lilly employees impacted by the transfer will have the opportunity to join Advion.

Financial terms of the transaction were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.